Core Viewpoint - The recent departure of Huang Bin, Vice President of AstraZeneca China, marks a significant shift in the company's leadership, following the exit of former China President Wang Lei. This change reflects ongoing adjustments within AstraZeneca's organizational structure in China, aimed at optimizing its strategic focus on next-generation innovative drugs, particularly in cell therapy and other advanced fields [3][4]. Group 1: Leadership Changes - Huang Bin's departure is part of a broader restructuring within AstraZeneca China, which has seen multiple high-level changes since Wang Lei's exit in 2024 [3][4]. - Huang Bin was a key figure in AstraZeneca's market access department, having participated in 26 national medical insurance negotiations, significantly impacting the inclusion of innovative drugs in China's healthcare system [3][4]. Group 2: Strategic Focus - AstraZeneca is actively restructuring to enhance its focus on next-generation innovative drugs, including the establishment of a commercial production and supply base for cell therapies in Shanghai [5]. - The company plans to invest over 100 billion RMB in China by 2030, indicating a strong commitment to expanding its operations and capabilities in the region [5].

Core Viewpoint - The company Fuhong Hanlin (02696) has announced the completion of the first patient dosing in a Phase 2/3 clinical study of HLX22 combined with HLX87 for the first-line treatment of HER2-positive recurrent or metastatic breast cancer in mainland China [1][2] Group 1 - The clinical study is an open-label, randomized, multi-center Phase 2/3 trial evaluating the efficacy of HLX22 combined with HLX87 in patients with HER2-positive recurrent or metastatic breast cancer [2] - The study consists of two phases: the first phase is a Phase 2 trial with a 2:2:1:1 randomization ratio for treatment groups, including HLX22 combined with HLX87, and various combinations of other therapies [2] - The primary endpoint of the first phase is the objective response rate (ORR) and progression-free survival (PFS) assessed by an independent imaging review committee (BICR) [2] Group 2 - The second phase is a Phase 3 trial with a 1:1 randomization ratio comparing HLX22 combined with HLX87 to other treatment combinations [2] - The primary endpoint of the second phase is PFS evaluated by BICR [2] - The main objective of the study is to assess the clinical efficacy of HLX22 combined with HLX87, with secondary objectives including safety, tolerability, pharmacokinetics (PK), immunogenicity, and exploration of potential predictive or resistance biomarkers [2]

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has announced the completion of the first patient dosing in a Phase 2/3 clinical study of HLX22 in combination with HLX87 for the treatment of HER2-positive recurrent or metastatic breast cancer in mainland China [1][2]. Group 1: Clinical Study Overview - The study is an open-label, randomized, multi-center Phase 2/3 clinical trial evaluating the efficacy of HLX22 combined with HLX87 in treating HER2-positive recurrent or metastatic breast cancer patients [2]. - The first phase involves a randomized, parallel-controlled design with a 2:2:1:1 allocation ratio for participants receiving HLX22 combined with HLX87, or other combinations including pertuzumab and trastuzumab [2]. - The primary endpoints for the first phase include objective response rate (ORR) and progression-free survival (PFS) assessed by an independent imaging review committee (BICR) [2]. Group 2: Study Objectives and Design - The second phase of the study is also an open-label, randomized, multi-center trial, with participants allocated in a 1:1 ratio to receive either HLX22 combined with HLX87 or pertuzumab combined with trastuzumab and docetaxel [2]. - The main objective of the study is to evaluate the clinical efficacy of HLX22 combined with HLX87 in treating HER2-positive recurrent or metastatic breast cancer, while secondary objectives include assessing safety, tolerability, pharmacokinetics (PK), immunogenicity, and exploring potential predictive or resistance biomarkers [2].

Group 1 - AstraZeneca disclosed multiple lawsuits related to personal information infringement and illegal trade in its 2025 annual report [1] - In October 2025, AstraZeneca (China) received a final assessment from Shenzhen Customs indicating unpaid import taxes totaling 24 million RMB (approximately 3.5 million USD) related to specific drugs [1] - AstraZeneca (China) prepaid the compensation amount in full, but could face fines of 1 to 5 times the unpaid import tax if found liable for illegal trade [1] Group 2 - In November 2025, the Shenzhen People's Procuratorate completed its assessment, leading to public prosecution of AstraZeneca (China), a former executive vice president, and a former senior employee for illegal collection of personal information and illegal trade [1] - The former executive vice president and senior employee were additionally charged with medical insurance fraud, although AstraZeneca (China) was not prosecuted for this charge [1] - The mentioned cases have been consolidated into a single litigation process at the Shenzhen Intermediate People's Court, with no trial date scheduled yet [1]

Group 1 - The National Health Commission and 11 other departments issued the "National Essential Drug Directory Management Measures," revising six key areas to enhance the essential drug system in China [1] - The revised measures include optimizing the directory structure, categorizing drugs into chemical drugs, biological products, and traditional Chinese medicine based on clinical pharmacology and functionality [1] - The management mechanism for the directory has been improved, emphasizing the clinical value of drugs and considering factors such as disease spectrum changes and drug supply assurance [1] Group 2 - Reborna Biotech and Madrigal Pharmaceuticals entered a global exclusive licensing agreement worth $4.4 billion to develop innovative siRNA therapies for metabolic dysfunction-related fatty liver disease (MASH) [2] - Reborna will receive a $60 million upfront payment and is eligible for additional payments upon achieving clinical development and regulatory milestones, along with royalties based on global net sales [2] - The agreement highlights the international value of domestic innovative drugs and the urgent demand for effective therapies in the MASH field, indicating significant market potential [2] Group 3 - Watson Bio announced plans to invest 450 million yuan to establish a biological industry investment fund, targeting a total fund size of 1 billion yuan [3] - The fund will primarily invest in the synthetic biology manufacturing sector, including areas such as synthetic biology, health, bio-agriculture, bio-energy, and bio-materials [3] - This initiative is expected to help Watson Bio capture industry benefits and lay the groundwork for future strategic mergers and acquisitions [3] Group 4 - Hengrui Medicine's subsidiary, Suzhou MSD Biopharmaceutical Co., has had its drug SHR-A1811 included in the list of breakthrough therapies by the National Medical Products Administration [4] - SHR-A1811 is intended for first-line treatment of locally advanced or metastatic non-small cell lung cancer patients with HER2 (ERBB2) activating mutations [4] - The inclusion of SHR-A1811 reflects Hengrui's research achievements in the ADC field, although it will face competition from several already approved similar products [4]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiary, Suzhou Merdia Biopharmaceutical Co., Ltd., has received inclusion of its injectable SHR-A1811 (Rocatinib) in the list of breakthrough therapies by the National Medical Products Administration (NMPA), marking the 10th indication for which it has received breakthrough therapy certification [1] Group 1: Drug Information - Drug Name: Injectable Rocatinib (SHR-A1811) [1] - Acceptance Number: CXSL2000087 [1] - Drug Type: Therapeutic biological product [1] - Registration Category: Class 1 [1] - Application Date: December 2, 2025 [1] - Proposed Indication: First-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 (ERBB2) activating mutations [1] Group 2: Approved Indications - The injectable Rocatinib was approved for domestic market launch in May 2025, indicated for adult patients with unresectable locally advanced or metastatic NSCLC who have previously received at least one systemic therapy and have HER2 (ERBB2) activating mutations [2] Group 3: Market Context - Primary lung cancer is the most common malignant tumor globally, with GLOBOCAN 2022 data indicating approximately 2.48 million new cases and 1.82 million deaths annually, making it the leading cause of cancer mortality [3] - In 2022, China reported 1.06 million new lung cancer cases, accounting for 22.0% of all malignant tumors, and 733,300 deaths, representing 28.5% of all cancer deaths [3] - NSCLC accounts for about 85% of lung cancer cases, with approximately 2%-4% of NSCLC patients experiencing HER2 mutations, which are associated with high tumor invasiveness and poor prognosis [3] - Recent advancements in antibody-drug conjugates and highly selective HER2-TKIs have provided new treatment options for patients with advanced NSCLC harboring HER2 mutations [3] Group 4: Drug Mechanism and Competition - Injectable Rocatinib binds to HER2-expressing tumor cells, inducing cell cycle arrest and apoptosis through the release of toxins in the tumor cell lysosome [4] - Competing intravenous products in the domestic market include Roche's Ado-trastuzumab emtansine, AstraZeneca and Daiichi Sankyo's Fam-trastuzumab deruxtecan, Rongchang Biopharmaceutical's Vidisichu monoclonal antibody, and Kelun-Biotech's Bodo-trastuzumab [4] - According to EvaluatePharma, the global sales of similar products are projected to reach approximately $6.557 billion by 2024 [4] - Cumulative R&D investment for injectable Rocatinib is approximately 1.7725 billion yuan (unaudited) [4]

Investment Rating - The report maintains a neutral rating for the biopharmaceutical industry, specifically focusing on the ADC (Antibody-Drug Conjugate) sector [1]. Core Insights - The global ADC market is experiencing rapid growth, with the total market size reaching approximately $10.4 billion in 2023 and projected to grow to $66.2 billion by 2030, reflecting a compound annual growth rate (CAGR) of over 30% [11]. - Domestic Chinese companies are catching up in ADC drug development, with the number of research pipelines expected to surpass that of the United States by 2024, positioning China as the leader in ADC research pipelines [11][16]. - Several domestic companies are optimizing ADC drugs by leveraging existing technologies and platforms developed by international firms, leading to the development of more effective and stable ADC products [7][9]. - Key targets for ADC drugs include HER2, TROP2, EGFR, and HER3, with multiple domestic companies showing promising clinical data for their pipelines in these areas [7][9]. Summary by Sections Section 1: Introduction to ADC Drugs - ADCs are a class of targeted cancer therapies that combine monoclonal antibodies with cytotoxic drugs, allowing for precise delivery of treatment to cancer cells while minimizing damage to normal cells [19]. Section 2: Domestic and International ADC Platforms - The report highlights the advancements made by domestic companies in establishing ADC platforms, with firms like Hengrui Medicine and Kolon Biotech leading the way in developing innovative ADC technologies [70][62]. Section 3: Popular Targets and Key Pipelines for ADC Drugs - Notable companies such as Hengrui Medicine and Kolon Biotech have developed ADCs targeting HER2 and TROP2, showing strong clinical efficacy in treating breast and lung cancers [7][9]. Section 4: Business Development (BD) Situations for Domestic ADC Drugs - The report notes an increasing trend of domestic ADC drugs being sought after by international firms, with the number of BD transactions for ADCs accounting for 12%-13% of total drug transactions from 2022 to 2024 [9]. Section 5: Related Companies and Investment Opportunities - The report suggests focusing on companies with established ADC platforms and promising product pipelines, including Hengrui Medicine, Kolon Biotech, BaiLi Tianheng, and China National Pharmaceutical Group [9].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a downward trend below the average [4][19] - The top three sub-industries by PE are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction of 2.125 billion yuan in shareholder holdings, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Review - The report highlights significant developments in the pharmaceutical retail sector, emphasizing the need for transformation from traditional drug sales to comprehensive health services [24][25] - The Ministry of Commerce and other departments issued opinions to promote high-quality development in the pharmaceutical retail industry, projecting a market size increase from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a growth of 22.4% [24][25] - The report also discusses the approval of new drugs and treatments, including the PD-1/VEGF bispecific antibody RC148 by Rongchang Biopharmaceuticals, which has a potential total payment of up to 4.95 billion USD [7][50] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation from high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADC, bispecific antibodies, and siRNA therapies [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a decline in valuation below the average [4][19] - The top three sub-industries by PE (TTM overall method, excluding negative values) are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction in shareholder holdings amounting to 2.125 billion yuan, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Trends - The 2026 JPM Conference highlighted Chinese innovative drugs as a global focus, with several Chinese companies showcasing advancements in PD-1/VEGF bispecific antibodies, ADCs, and cell therapies [7] - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation through high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADCs, bispecific antibodies, and siRNA therapies [7] Important Industry News - The Ministry of Commerce and eight other departments issued opinions on promoting high-quality development in the drug retail industry, projecting a growth in the drug circulation market from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a 22.4% increase [24] - The National Healthcare Security Administration released guidelines for pricing projects related to surgical and treatment auxiliary operations, aiming to standardize and promote the use of advanced medical technologies [27][28] - Notable approvals include Daiichi Sankyo's "Trastuzumab Deruxtecan" for advanced HER2-positive gastric cancer, and AbbVie’s "Risankizumab" for ulcerative colitis, showcasing significant advancements in treatment options [38][44]

Core Viewpoint - The article discusses the investment framework for the pharmaceutical industry ETF in 2026, emphasizing a dual-driven approach of demand and innovation to navigate the market recovery and differentiation after a prolonged bear market since 2021 [29]. Market Review - The CITIC Pharmaceutical Index decreased by 0.38%, outperforming the CSI 300 Index by 0.24 percentage points, ranking 25th among 30 primary industries [9]. - The top ten stocks by increase this week included ST Changyao, Hualan Biological Engineering, and Kangzhong Medical, with gains ranging from 6% to 70.38% [9]. - The bottom ten stocks by decrease included Kain Technology and Aidi Pharmaceutical, with declines of up to 45% [9]. Industry and Stock Events - The article highlights a shift in funding from active to passive management in the pharmaceutical sector, with passive funds becoming a significant part of the long-term funding structure [18]. - The article notes that the innovation drug sector is expected to see a transition from quantity to quality, focusing on differentiated products and internationalization by 2025 [12]. - The medical device sector is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is benefiting from policies promoting home medical devices and accelerated overseas expansion [12]. - The article discusses the favorable conditions for the blood products industry, with relaxed approval for plasma stations and a clear growth path for the industry during the 14th Five-Year Plan period [13]. Investment Strategy - The article proposes a dynamic ETF configuration framework for the pharmaceutical sector, categorized into three layers: a core base of broad-based ETFs, a dual-driven layer focusing on innovative drugs and medical devices, and a defensive layer using traditional Chinese medicine and overseas biotech [22]. - The article emphasizes the importance of a systematic approach to ETF selection, considering liquidity, tracking quality, and cost [24]. - It suggests that the pharmaceutical sector is entering a new growth cycle driven by rigid demand and continuous innovation, necessitating a more structured and rhythmic ETF combination strategy [22].